ANTI-PLATELET THERAPY PERSPECTIVES

1. Grothusen C, Umbreen S, Konrad I et al. EXP3179 inhibits collagen-dependent platelet activation via GP receptor-VI independent of AT-I-receptor antgonism: potential impact on atherothrombosis. Circulation 2007; 27:1184-1190

2. Ono K, Ueda H, Yoshizawa Y et al. Structural basis for platelet anti-aggregation by angiotensin II type 1 receptor antagonist losartan via glycoprotein VI. J. Med. Chem. 2010 Mar; 53(5):2087-93

3. Munch G, Bultmann A, Rosport K et al. Revacept (dimeric GPVIFc) does not alter bleeding time in humans, but effectively inhibits collagen-induced platelet aggregation. Circulation 2010 Nov; 122: A14971

4. Zafar MU, Ibanez B, Choi BG et al. A new oral antiplatelet agent with potent antithrombotic properties: comparison of DZ-697b with clopidogrel a randomized phase I study. J. Thromb. Hemost. 2010; 103(1):205-12

5. Bartunek J, Barbato E, Vercruysse K et al. Safety and efficacy of anti-von Willebrand factor Nanobody ALX-0081 in stable angina patients undergoing percutaneous coronary intervention. Circulation 2010 Nov 23; 122: A15084

6. Fibras C, Siller-Matula JM, Jilma B. Targeting von Willebrand factor and platelet GPIb receptor. Expert Rev. Cardiovasc. Ther. 2010 Dec; 8(12):1689-1701

7. Gilbert JC, DeFeo-Fraulini T, Hutabarat RM et al. First-inhuman evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers. Circulation 2007; 116:2678-2686

8. Arzamendi D, Dandachii F, Theoret JF et al. An anti-von Willebrand factor aptamer reduces platelet adhesion among patients receiving aspirin and clopidogrel in an ex vivo shear-induced artrial thrombosis. Clin. Appl. Thromb. Hemost. 2010 Nov 15

9. Mayr FB, Knobl P, Jilma B et al. The aptamer ARC1779 blocks von Willebrand factor-dependent platelet function in patients with thrombotic thrombocytopenic purpura ex vivo. Transfusion. 2010; 50(5):1079-1087

10. Spiel AO, Gilbert JC, Jilma B. Von Willebrand factor in cardiovascular disease: focus on acute coronary syndromes. Circulation 2008; 117:1449-1459

11. Staelens S, Desmet J, Ngo TH et al. Humanization by variable domain resurfacing and grafting on a human IgG4, using a new approach for determination od non-human like surface accessible framework residues based on homology modelling of variable domains. Mol. Immunol. 2006; 43(8):1243-57

12. Meyer De SF, Staelens S, Badenhorst PN et al. Coronary artery in-stent stenosis persists despite inhibition of the von Willebrand factor-collagen interaction in baboons. Thromb. Haemost. 2007; 98(6):1343-1349

13. Fontayne A, Meiring M, Lamprecht S et al. The humanized anti-glycoprootein Ib monoclonal antibody h6B4-Fab is a potent and safe antithrombotic in a high shear arterial thrombosis model in baboons. Thromb. Haemost. 2008; 100(4):670-677

14. Wadanoli M, Sako D, Shaw GD et al. The von Willebrand factor antagonist (GPG-290) prevents coronary thrombosis without prolongation of bleeding time. Thromb. Haemost. 2007; 98(2):397-405

15. Yang J, Ji S, Dong N et al. Engineering and characterization of a chimeric anti-platelet GP Ib-alpha monoclonal antibody and preparation of Fab fragment. Hybridoma (Larchmt) 2010 Apr; 29(2):125-132

16. Lasser G, Guchait P, Ellsworth JL et al. C1qTNF-related protein-1: a vascular wall protein that inhibits collagen-induced platelet aggregation by blocking vWF binding to collagen. Blood 2006; 107(2):423-430

17. Hennerici MG, Bots ML, Ford I et al. Rationale, design and population baseline characteristics of the PERFORM vascular project: an ancillary study of the prevention of CV events of ischemic origin with terutroban. Cardiovasc. Drugs Ther. 2010; 24:175-180

18. Cocheri S. Antiplatelet drugs – do we need new options? With a reappraisal of direct thromboxane inhibitors. Drugs 2010; 70(7):887-908

19. Leonardi S, Rao SV, Harrington RA et al. Rationale and design of the randomized, double-blind trial testing intravenous and oral administration of elinogrel versus clopidogrel in nonurgent PCI patients (INNOVATE-PCI). Am. Heart J. 2010 Jul; 160(1):65-72

20. Post JM, Alexander S, Wang YX et al. Novel P2Y12 adenosine diphospahte receptor antagonists for inhibition of platelet aggregation (II). Thromb. Res. 2008; 122(4):533-540

21. Watanabe H, Nakagawa K, Kakihana M. Effects of sarpogrelate, a selective serotonin receptor antagonist, on vascular function and renal function in diabetic patinets with stabel angina and chronic kidney disease. Circulation 2009; 120: A4563

22. Nakamura K, Kawahito K. Erythrocyte-protective effect of sarpogrelate hydrochloride (Anplag), a selective 5-HT2 receptor antagonist: an in vitro study. J. Artif. Organs. 2010 Sep; 13(3):178-181

23. Backer de T, Vander SR, Lehert P et al. Naftidrofuryl for intermittent claudication: meta-analysis based on individual patient data. BMJ 2009; 338: b46

24. Higashi Y, Fujita M, Origasa H et al. Study design of SEASON registry: prospective surveillance of CV events in antiplatelet treated arteriosclerosis obliterans patients in Japan. Int. Heart J. 2010; 51(5):337-342

25. Goto Sh, Ogawa H, Takeuchi M et al. Double-blind, placebo-controlled Phase II studies of PAR-1 antagonist E555 (atoxapar) in Japanese patients with ACS or high-risk CAD. Eur Heart J, 2010; 31:2601-2613

26. Goto Sh, Yamaguchi T, Ikeda Y et al. Safety and exploratory efficacy of the novel thrombin receptor (PAR-1) antagonist SCH530348 for NSTE ACS. J Atheroscler Thromb, 2010; 17:156-164

27. Chintala M, Strony J, Yang B et al. SCH 602539, a PAR-1 antagonist, inhibits thrombosis alone and in combination with cangrelor in a Folts model of arterial thrombosis in cynomologus monkeys. Arterioscler Thromb Vasc Biol, 2010 Nov; 30(11):2143-9

28. Schafer A, Fraccarollo D, werner L et al. Guanylyl cyclase activator ataciguat improves vascular function and reduces platelet activation in heart failure. Pharmacol. Res. 2010 Nov; 62(5):432-438

29. Burke SG, Wainwright CL, Vojnovic I et al. The effect of NCX4016 on the consequences of ischemia and reperfusion in the streptozotocin diavetic rat. J. Pharmacol. Exp. Ther. 2006; 316(3):1107-1114

30. Inoue Y, Sigano N, Jibiki M et al. Effects of cilostazol and K-134 on reconstructive surgery using prostetic grafts in the abdominal aorta of beagle dogs. Thromb. Res. 2008; 123(1):122-129